Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has reported Operating Leases for 8 consecutive years, with $61.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 23.72% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (down 23.72% YoY), while the FY2025 annual figure was $66.8 million, down 64.81% from the prior year.
• Operating Leases slipped to $61.4 million in Q1 2026 per NTLA's latest filing, from $66.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $190.0 million in Q4 2024 and bottomed at $60.0 million in Q2 2022.
• Historically, Operating Leases has averaged $90.6 million across 5 years, with a median of $84.1 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Leases surged 96.34% — and 2025, when it tumbled 64.81%.
• Intellia Therapeutics' Operating Leases stood at $114.0 million in 2022, then dropped by 15.15% to $96.7 million in 2023, then surged by 96.34% to $190.0 million in 2024, then sank by 64.81% to $66.8 million in 2025, then retreated by 8.16% to $61.4 million in 2026.
• Business Quant data shows NTLA's Operating Leases at $61.4 million in Q1 2026, $66.8 million in Q4 2025, and $70.6 million in Q3 2025.